Diabetes expert accuses drug company of “intimidation”BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39409.458611.DB (Published 29 November 2007) Cite this as: BMJ 2007;335:1113
- Bob Burton
The former chairman of research and development at GlaxoSmithKline, Tadataka Yamada, has been asked by a US Senate committee to explain his role in what it describes as the “intimidation” of John Buse, a professor of medicine at the University of North Carolina.
In 1999 Dr Buse raised questions about the cardiovascular safety of the diabetes drug rosiglitazone, which is marketed as Avandia (BMJ 2007;334:1237 doi: 10.1136/bmj.39244.394456.DB). He was speaking at a symposium organised by the American Diabetes Association.
A report by the Senate Finance Committee staff has shown that a company official emailed Dr Yamada proposing that a “firm letter” be written to Dr Buse containing a warning that “the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial